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In Brief
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human neuromuscular junctions (NMJs)
are smaller and more fragmented than
comparable synapses from mice, with a
distinct molecular composition. In
contrast to mice, human NMJs were also
remarkably stable across the entire adult
lifespan.
Cell Reports
ReportCellular and Molecular Anatomy
of the Human Neuromuscular Junction
Ross A. Jones,1,2 Carl Harrison,3 Samantha L. Eaton,4 Maica Llavero Hurtado,4 Laura C. Graham,4 Leena Alkhammash,1
Oladayo A. Oladiran,1 Andy Gale,1 Douglas J. Lamont,5 Hamish Simpson,6 Martin W. Simmen,1 Christian Soeller,3
Thomas M. Wishart,2,4 and Thomas H. Gillingwater1,2,7,*
1Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK
2Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh EH8 9AG, UK
3Physics and Astronomy, University of Exeter, Exeter EX4 4QL, UK
4Neurobiology, Roslin Institute, University of Edinburgh, Edinburgh EH25 9RG, UK
5Fingerprints Proteomics, University of Dundee, Dundee DD1 5EH, UK
6Department of Orthopaedic Surgery, University of Edinburgh, Edinburgh EH16 4SB, UK
7Lead Contact
*Correspondence: t.gillingwater@ed.ac.uk
https://doi.org/10.1016/j.celrep.2017.11.008SUMMARY
The neuromuscular junction (NMJ) plays a funda-
mental role in transferring information from lower
motor neuron to skeletal muscle to generate move-
ment. It is also an experimentally accessible model
synapse routinely studied in animal models to
explore fundamental aspects of synaptic form and
function. Here, we combined morphological tech-
niques, super-resolution imaging, and proteomic
profiling to reveal the detailed cellular and molecular
architecture of the human NMJ. Human NMJs were
significantly smaller, less complex, and more frag-
mented than mouse NMJs. In contrast to mice, hu-
man NMJs were also remarkably stable across the
entire adult lifespan, showing no signs of age-related
degeneration or remodeling. Super-resolution imag-
ing and proteomic profiling revealed distinctive dis-
tribution of active zone proteins and differential
expression of core synaptic proteins and molecular
pathways at the human NMJ. Taken together, these
findings reveal human-specific cellular and molecu-
lar features of the NMJ that distinguish them from
comparable synapses in other mammalian species.
INTRODUCTION
Synapses play fundamental roles in the form and function of the
nervous system both in health and during disease. Despite
numerous important breakthroughs in our understanding of the
cellular and molecular composition of synapses in animal
models, both historic (Fatt and Katz, 1952; Couteaux and
Pe´cot-Dechavassine, 1970; Nitkin et al., 1987) and recent (Oh
et al., 2014; Wilhelm et al., 2014; Kasthuri et al., 2015), we
know surprisingly little about the equivalent make up of synapses
in humans. Current studies of synaptic connectivity at the cellular
and molecular level have therefore relied heavily on ‘‘model’’
organisms, both vertebrate and invertebrate, working on the2348 Cell Reports 21, 2348–2356, November 28, 2017 ª 2017 The A
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ultimately be applied to humans.
The neuromuscular junction (NMJ) represents one major sub-
class of synapse in the mammalian nervous system, critical for
the transfer of information between the nervous system (lower
motor neuron) and skeletal muscle. It also epitomizes a ‘‘model’’
synapse (Shi et al., 2012), both conveniently accessible within
the peripheral nervous system and an early target in several
neurodegenerative conditions, including amyotrophic lateral
sclerosis and spinal muscular atrophy (Murray et al., 2010).
Indeed, many of the fundamental principles governing synaptic
form and function in the nervous system were discovered from
early experiments examining NMJs in model organisms (Slater,
2015). More recently, the NMJ has been used to reveal core as-
pects of synaptic form and function in vivo, including the control
of activity-dependent plasticity (Newman et al., 2017), as well as
synaptic development and age-related decline (Liu et al., 2017).
Surprisingly, however, compared to extensive experimental
data from animal models, there is currently a relative paucity of
data concerning the cellular and molecular composition of the
humanNMJ. Ethical considerations and the logistics of obtaining
biopsy material (in contrast to post-mortem sampling) from
healthy individuals during life make it difficult to obtain tissue
samples that are suitably well-preserved to facilitate high-resolu-
tion cellular and molecular analysis (Kay et al., 2013). Here, we
report the development of a tissue harvesting and processing
approach during surgical amputation that has allowed us to
undertake a detailed cellular and molecular characterization of
the healthy human NMJ across the adult lifespan.
RESULTS AND DISCUSSION
Tissue samples were obtained from surgical discard material
from twenty patients undergoing lower limb amputation for a
variety of clinical indications (for full patient details, see Experi-
mental Procedures; summarized in Table S2), including
complications of peripheral vascular disease (PVD) and non-
PVD-related cases (e.g., for chronic pain following previous
orthopedic surgery or chronic osteomyelitis refractory to anti-
biotic treatment). Importantly, samples were obtained fromuthor(s).
commons.org/licenses/by/4.0/).
(legend on next page)
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non-pathological—otherwise healthy—regions of limb (e.g.,
close to the site of amputation) where the tissue needs to be
free from any disease or pathology in order for sufficient post-
operative tissue healing to occur. NMJs from four anatomically
distinct muscles were harvested: extensor digitorum longus
(EDL), soleus (S), peroneus longus (PL), and peroneus brevis
(PB). For comparison, the same muscles were dissected from
a single litter of young adult CD1 mice. NMJs were immunohis-
tochemically labeled, imaged, and analyzed using a standard-
ized platform: ‘‘NMJ-morph’’ (Jones et al., 2016). For each
NMJ, 21 individual synaptic variables were measured. Baseline
data were obtained for 2,860 human NMJs across seven
decades of life (from the ages of 34–92 years).
Cellular Architecture of the Human NMJ
Initial qualitative observations revealed striking morphological
differences between human and mouse NMJs (Figure 1). Human
NMJs were universally smaller than their mouse counterparts,
with much thinner pre-terminal axons, more rudimentary nerve
terminals, and distinctive ‘‘nummular’’ (formed of coin-shaped
patches) endplates (Figure 1). These observations were
confirmed quantitatively (Table S1). Axon diameter and average
area of AChR clusters showed the greatest differences between
species (3.69-fold**** and 3.33-fold****, respectively; higher in
mice), with over half of the morphological variables studied (12
of 21) showing a fold difference of at least 150% between hu-
mans and mice. The degree of overlap between pre- and post-
synaptic components (the proportion of AChR labeling at the
motor endplate that is directly covered by overlying motor nerve
terminal) was relatively similar between the species (50% in
humans, 64% in mice), in agreement with previous electron
microscopy (EM) studies (Slater et al., 1992). None of the human
NMJs analyzed lacked pre-synaptic boutons overlying AChR
clusters (Figure 1); the only difference was the degree to which
AChRs were dispersed beyond the limits of the nerve terminals.
Thus, each and every individual AChR island at the motor end-
plate was innervated by a corresponding motor nerve terminal
bouton. Importantly, no significant morphological differences
at the human NMJ could be attributed to patient co-morbidities
(diabetes mellitus, vascular disease) (Figure 1; also see Experi-
mental Procedures), and the side of the body examined did not
influence morphology (Figure 1), consistent with our previous
findings in mice (Jones et al., 2016).
Although human NMJs were routinely only half the size of their
mouse counterparts, with axons only a third of the caliber, theyFigure 1. Unique Morphology of the Human NMJ
(A) Representative confocal micrographs from 4 lower limbmuscles. Human NMJs
‘‘nummular’’ endplate. Scale bar, 10 mm.
(B) Bar charts demonstrating significant species-specific differences across a ran
of >600 human NMJs (and 240 mouse NMJs). Unpaired t test and Mann-Whitne
(C) Scatterplots showing correlation between nerve terminal area and axon/mus
(72 human and 24 mouse muscles). NMJ morphology was more closely correlate
Pearson correlation.
(D) Left/right muscles pairs from the same human casewere compared with 3mou
intervening line is the mean of the 2 sides. Laterality did not influence NMJ morp
(E). Effect of co-morbidities on human NMJ morphology. No significant morph
peripheral vascular disease (PVD). Unpaired t tests.
****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
2350 Cell Reports 21, 2348–2356, November 28, 2017were found to innervate muscle fibers up to twice the diameter
of those in mice (Figure 1). We therefore assessed the relation-
ship between NMJmorphology and pre- and post-synaptic cells
by correlating each morphological variable with motor axon
diameter and muscle fiber diameter respectively. In both
species, NMJ morphology correlated more strongly with motor
axon diameter (Jones et al., 2016) (Figure 1; Table S1). Correla-
tion coefficients (r) were higher in relation to axon diameter for
the majority of NMJ variables in both species (10 of the 18),
with only a minority (6 in humans, 1 in mice) being more closely
correlated with the muscle fiber, suggesting that the morpholog-
ical properties of the motor neuron (as determined by measuring
axon diameter) exerted a stronger influence on synaptic
morphology in humans than morphological properties of the
skeletal muscle fiber.
To confirm that the differences in NMJ morphology we
observed between humans andmicewere a consistent observa-
tion between humans and other mammals, we also compared
our human andmousedatawithNMJs fromadult rats (Figure S1).
Here, NMJ morphology was virtually indistinguishable between
mice and rats across all muscles examined, with both species
being clearly distinctive from humans. In addition, this compari-
son allowed us to establish whether the relatively small size of
human NMJs is simply a consequence of increased body size.
As an adult rat is considerably larger than a comparable mouse
(10-fold increase in body weight), if NMJ size was inversely
correlated with body size, we would have expected rat NMJs
to be notably smaller than mouse NMJs (e.g., an intermediate
NMJ size, somewhere between mice and humans). As NMJs
from mice and rats were morphologically indistinguishable
from each other, we conclude that the smaller size of human
NMJs cannot simply be a consequence of increased body size
and mass (Figure S1).
Taken together, these findings reveal that human NMJs have a
unique morphology, being significantly smaller and more frag-
mented than comparable synapses from widely used animal
models (mice and rats). This challenges the simplistic assump-
tion that structures in the human nervous system are inevitably
larger and more complex than those in lower mammals.
The Human NMJ across the Lifespan
One area of research that is currently receiving significant
interest concerns an apparent age-related decline in synaptic
stability at the NMJ, manifesting as degenerative changes
affecting both the pre-synaptic motor nerve terminal and theare smaller, with a thinner axon, less complex nerve terminals and a distinctive
ge of pre- and post-synaptic variables. Each bar represents the mean (±SEM)
y test.
cle fiber diameter. Each data point is an individual muscle (mean of 40 NMJs)
d with structural features of the pre-synaptic cell (motor axon) in both species.
se controls. Each data point (in the pair) is an individual muscle (left or right); the
hology in either species.
ological differences could be attributed to either diabetes mellitus (DM) or
Figure 2. The Human NMJ Is Stable across the Lifespan
(A) Representative confocal micrographs of human NMJs from the 4th to the 10th decades of life (all from peroneus longusmuscle). Despite the heterogeneity of
individual NMJs, the overall appearance is conserved across the 70+ year age range. Scale bar, 10 mm.
(B) Scatterplots showing correlations between age and a range of individual pre- and post-synaptic NMJ variables. Data are pooled across the 4 muscle groups
(72 individual muscles). Each data point is an individual muscle (mean of 40 NMJs). Although 2 of the pre-synaptic variables shown correlated with age (a modest
increase in the size of the pre-synaptic axon and motor nerve terminal), overall synaptic morphology remained remarkably stable. Pearson and Spearman
correlation.
****p < 0.0001, ***p < 0.001.post-synaptic motor endplate (Gonzalez-Freire et al., 2014; Liu
et al., 2017). Although findings from animal models (Anis and
Robbins, 1987; Balice-Gordon and Lichtman, 1990; Valdez
et al., 2010; Willadt et al., 2016) suggest that NMJs are inherently
unstable with age, it is unclear whether a similar phenomenon
occurs across the longer human lifespan. We were able to
address this important question as our human tissue samples
incorporated patients from the fourth to the tenth decades of
life, with the individual ages of patients distributed approximately
evenly across the age range (Table S2).Qualitative analyses of NMJs suggested conservation of syn-
aptic structure across the entire lifespan in humans (Figure 2).
The only change observed with increasing age was a modest in-
crease in axon diameter (r = 0.529****) (Figure 2). Notably, there
was no significant change in muscle fiber diameter or endplate
area with age. Nor were there any age-associated changes in
the degree of overlap between pre- and post-synaptic compo-
nents of the NMJ, or any evidence for age-associated fragmen-
tation of the NMJ (Figure 2). Furthermore, the modest degree of
pre-synaptic remodeling that occurred with age was de-coupledCell Reports 21, 2348–2356, November 28, 2017 2351
from equivalent changes in the muscle fiber, further supporting
our finding that synaptic morphology is more closely correlated
with the pre-synaptic neuron. Thus, the human NMJ remains
remarkably stable across the adult lifespan, devoid of any of
the age-related degeneration and/or remodeling changes that
have been reported in other mammalian species occurring
over a much shorter time scale (Valdez et al., 2010; Willadt
et al., 2016).
Interestingly, these findings partially contradict an earlier study
suggesting that the human NMJ undergoes changes over the
adult lifespan (Oda, 1984). These differences are most likely
explained by methodological disparities between the studies
and a smaller sample size in the Oda (1984) study. For example,
Oda used relatively low-resolution techniques (e.g., silver and
cholinesterase staining) to study 12 autopsy samples obtained
6 hr after death. Our own preliminary experiments confirmed
that we needed to harvest tissue quickly (e.g., within minutes)
from freshly biopsied material (not post-mortem) in order to
obtain accurate morphological measurements. Moreover, our
findings are in agreement with another smaller study of human
muscle samples where endplate size was found to remain stable
with age (Wokke et al., 1990).
Super-Resolution (Direct Stochastic Optical
Reconstruction Microscopy) Imaging of Active Zone
Proteins at the Mouse and Human NMJ
Given the structural differences we observed between human
and mouse NMJs, we next wanted to establish whether human
NMJs were also distinct from the molecular perspective. In our
initial morphological experiments, labeling of the synaptic
vesicle protein SV2 appeared to be qualitatively different
between human and mouse nerve terminals. Synaptic boutons
in mice were characterized by relative homogeneity of labeling,
whereas motor nerve terminals at human NMJs contained
distinctive ‘‘hotspots’’ of fluorescence (particularly clear exam-
ples can be seen in the 2H3/SV2 greyscale panels for the 4th,
7th, and 9th decade images shown in Figure 2). Because the func-
tional architecture of active zones varies considerably between
species (Ackermann et al., 2015), we hypothesized that the
heterogeneous labeling of SV2 in humans reflected differential
spatial arrangement of active zone proteins/material at human
synapses.
We assessed active zone protein distribution in human NMJs
by performing direct stochastic optical reconstruction micro-
scopy (dSTORM) super-resolution imaging (Huang et al., 2010)
of one key active zone protein (SNAP25). SNAP25 is a compo-
nent of the SNARE complex, a series of structural proteins
responsible for the fusion of synaptic vesicles with the plasma
membrane during exocytosis (Han et al., 2017), that is also
known to be localized to active zones in vivo (Wilhelm et al.,
2014). dSTORM imaging at the mouse NMJ revealed a remark-
ably similar punctate distribution of SNAP25 to that previously
reported from studies of other active zone proteins in a variety
of species using a range of different techniques (Fukunaga
et al., 1983; Meinertzhagen et al., 1998; Nagwaney et al.,
2009). For example, quantitative comparisons between our
mouse SNAP25 data and recent data from STED microscopy
experiments studying the active zone proteins Bassoon and2352 Cell Reports 21, 2348–2356, November 28, 2017Piccolo in mice (Nishimune et al., 2016) revealed remarkably
similar subcellular distribution: the average density of Bassoon
and Piccolo ‘‘puncta’’ in the Nishimune et al. (2016) study was
10 per mm2, with similar analyses of SNAP25 in our study
revealing a density of 15 per mm2.
The finding that dSTORM imaging could be used to reliably
label and quantify SNAP25 distribution at the mouse NMJ
prompted us to apply dSTORM imaging to compare SNAP25
localization betweenmouse and humanNMJs. Parallel dSTORM
imaging of human andmouse NMJs revealed clear differences in
the distribution and intensity of SNAP25 between the two spe-
cies (Figure 3). We quantified a total of 2,945 (human) and
10,666 (mouse) individual SNAP25 puncta, from 50 boutons
(10 NMJs) of 3 individual patients/mice. All four core variables
measured were found to be significantly greater in humans
than in mice: the average area of individual SNAP25 puncta
and their density within each bouton (both **p < 0.01), the total
area of all puncta relative to that of each bouton (****p <
0.0001), and the intensity of SNAP25 labeling (****p < 0.0001).
Given that motor nerve terminals (and hence the ‘‘area of syn-
aptic contact’’) at the human NMJ are significantly smaller than
those in mice (Figure 1; Table S1), we calculated the total area
of SNAP25 labeling per NMJ. This analysis revealed the total
area to be identical in both humans and mice: approximately
15 mm2 of SNAP25 per NMJ (Figure 3). Therefore, although the
human NMJ is significantly smaller than the mouse NMJ, the
total amount of SNAP25 protein (and, by extension, the amount
of molecular active zone machinery) is similar between human
and mouse NMJs, albeit packaged into significantly smaller syn-
aptic boutons in humans. This observation suggests the possible
presence of a homeostatic mechanism that preserves the func-
tional architecture of the synapse in the face of significant
morphological heterogeneity. In conjunction with the extensive
post-synaptic junctional folding demonstrated previously (Slater
et al., 1992), this pre-synaptic specialization could play a role in
effectively maintaining neurotransmission at the smaller human
NMJ. The application of super-resolution imaging to visualize
active zone proteins at the human NMJ reported here paves
the way for future studies that will be able to develop a more
refined and detailed subcellular ‘‘map’’ of synaptic protein distri-
bution and localization across different species. Such studies
may also assist in addressing the apparent discrepancies that
exist between the species-specific differences we report with
respect to the molecular composition of active zones and previ-
ous freeze-fracture studies that suggested more consistent con-
servation of gross active zone structure between human and
rodent synapses (for review see Rogers and Nishimune, 2017).
Of note, we were unable to reliably label human NMJs with anti-
bodies against Bassoon or Piccolo, which may point to species-
specific differences in these antigens.
Molecular Profiling of the Human NMJ
To investigate potential differences in the broader species-spe-
cific molecular composition of the human NMJ, we next utilized
state-of-the-art proteomic techniques (tandem mass tagging) to
undertake comprehensive proteome-wide profiling of human
and mouse NMJs. By establishing the proteomic profile of mi-
cro-dissected NMJ-enriched and NMJ-devoid skeletal muscle
Figure 3. Comparative Super-Resolution (dSTORM) Imaging of the Active Zone Protein SNAP25 at Human and Mouse NMJs
(A and E) Composite images of SNAP25-labeled nerve terminals (dSTORM, orange/red) overlaid on BTX-labeled AChRs of the motor endplate (wide-field, gray).
Note that (A) only shows two single synaptic boutons from the human NMJ (not the whole NMJ), and (B) only shows a sub-region of one single synaptic bouton
from the mouse NMJ (again not the whole NMJ). Scale bars, 1 mm.
(B and F) 8-bit greyscale images of single boutons (representing the areas contained within the red boxes in A and E) used to quantify intensity of labeling (I). Note
the increased intensity and density of SNAP25 in the human NMJ. Scale bars, 500 nm.
(C and G) Despeckled, binary versions of (B) and (F) used to quantify the remaining variables (J–L). The boxed areas have been enlarged (D and H) to depict
individual SNAP25 puncta; 10 discrete puncta have been labeled in each image. Scale bars, 100 nm.
(I–L) Bar charts showing dSTORM image quantification of SNAP25 intensity (I), density of SNAP25 puncta (J), average area of SNAP25 puncta (K), and the area of
SNAP25 puncta as a percentage of total bouton area (L), at human and mouse NMJs. All 4 measures of SNAP25 labeling were significantly greater in the human
NMJs. For both human and mouse datasets, n = 50 boutons; bar charts depict mean (±SEM). Unpaired t test and Mann-Whitney test.
(M and N) Bar charts comparing the average size of human andmouse NMJs (nerve terminal area, M) with the total size of their active zonematerial (SNAP25 area
per NMJ, N). Although the humanNMJ is significantly smaller than themouseNMJ (M), the total amount of SNAP25 labeling at the NMJ is the samewhen adjusted
to reflect the total overall size of the synapse (N). Unpaired t test.
****p < 0.0001, **p < 0.01.samples (Figures 4 and S2), we were able to establish and
compare the protein-level composition of NMJs and muscle
fibers in human and mouse samples. Through a combined hu-
man/mouse database search we confirmed the identification of
peptides associated with 6,737 proteins. Application of stringent
filtering parameters in order to ensure reliability of protein identi-
fication subsequently yielded 5,026 proteins for bioinformatics
analyses. This represents a high level of coverage from a single
proteomic analysis and compares favorably with a recent data-
base of human muscle proteins identified by mass spectrometry
that lists 5,431 muscle proteins across 38 peer reviewed scien-
tific publications from 2002–2017 (Gonzalez-Freire et al., 2017).
Moreover, we were able to demonstrate the identification of
synaptic and neuronal proteins within our NMJ-enriched dissec-
tions (Figures S3 and S4).
Comparative bioinformatics analysis of proteomic profiles
from human and mouse skeletal muscle samples (devoid of
NMJs) revealed clear molecular overlap (Figure 4; Table S3),
with the majority (66%) of the 200 known metabolic cascades
identified showing no significant species-dependent differ-ences. In contrast, the expression profiles for the NMJ-enriched
samples indicated a clear molecular variation between humans
and mice (Figure 4). For example, in silico analysis identified 36
distinct nervous system-related molecular pathways known to
impact on NMJ form and function (including a range of core
synaptic signaling pathways, such as ‘‘integrin signaling,’’
‘‘axonal guidance signaling,’’ and ‘‘CREB signaling in neurons’’)
where proteins were present in both human andmouse datasets.
Surprisingly, 97% of these pathways showed statistically signif-
icant differences in protein expression levels between the two
species (Figures 4 and S4). For example, major differences
were observed in the levels of 24 individual proteins contributing
to agrin signaling pathways at the NMJ (Figure S4). Importantly,
each affected pathway included some proteins that were more
abundant in human samples as well as other proteins that
were more abundant in mouse samples, confirming that the dif-
ferences observed were not simply an artifact of relative enrich-
ment during tissue processing. Thus, these proteomics datasets
provide evidence to suggest that human NMJs have a signifi-
cantly modified molecular composition compared to analogousCell Reports 21, 2348–2356, November 28, 2017 2353
Figure 4. Unique Molecular Profile of the Human NMJ
(A) Schematic representation of sample micro-dissection used to produce NMJ-enriched and NMJ-devoid (muscle) samples for proteomics and subsequent
bioinformatics analysis. NMJ presence/absence was confirmed by a-bungarotoxin labeling (Experimental Procedures).
(B) Heatmap representation of proteomic data. Abundance is indicated by color intensity, from lowest (darkest blue) to highest (darkest red). Clear differences
exist between the 4 samples, particularly when comparing human and mouse NMJs.
(C) Schematic representation of proteomic data based on Biolayout output (Experimental Procedures). Each sphere represents the entire expression data for an
individual tissue sample, and the proximity and orientation relative to one another indicates the similarity of the datasets; human and mouse muscle samples are
more similar than human and mouse NMJ samples.
(D) In silico analysis identifies canonical cascades relating to neurotransmitter function and nervous system signaling. Ten example pathways are listed. Values
are the percentage (and number) of proteins in each cascade that are upregulated (red) or downregulated (blue) in human cf. mouse. Significance levels are listed
as –log10(p value), i.e., –log10(p < 0.05)z1.3, –log10(p < 0.0001) = 4, etc. Of the 36 pathways identified, only 1 showed no significant species difference (GABA
receptor signaling cascade; not shown).NMJs in mice. This finding is consistent with recent observations
of species-specific gene expression in developing neurons from
humans and mice (Qiu et al., 2016).
Taken together, our findings reveal human-specific features of
the NMJ that distinguish them from comparable synapses in
other mammalian species. These fundamental differences
between synapses in humans and lower mammals must be
taken into careful consideration when interpreting animal-based
studies with respect to their applicability to humans.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in
Supplemental Experimental Procedures.
Ethics
Use of anonymous human tissue was granted by the Lothian NRS
BioResource (SR719, 15/ES/0094); prospective tissue collection was
approved by the Lothian Ethics Committee (REC 2002/1/22, 2002/R/OST/
02) following internal (University of Edinburgh) and independent/external
ethical review.
Human Case Series
Human muscle samples were obtained from patients following lower limb
amputation surgery (see above for ethical/institutional approvals). In total, 212354 Cell Reports 21, 2348–2356, November 28, 2017sets of muscle samples were obtained from 20 patients (15 male, 5
female)—1 patient required a bilateral procedure. The clinical details for
each patient are summarized in Table S2. The majority of patients (16 out of
20) underwent amputation for complications of peripheral vascular disease
(PVD), typically either critical ischemia in a non-salvageable limb, or failure of
previous vascular reconstruction. Most of these cases (12 out of 16) were
below-knee amputations (BKA); only four patients required above-knee ampu-
tation (AKA). Of the four non-PVD-related cases, BKA was performed in two
patients for chronic pain following previous orthopedic surgery (49F, 50M),
in one patient for chronic osteomyelitis refractory to antibiotic treatment
(42F) and in a final patient (34M) who required bilateral amputation for acute
ischemia (secondary to thromboembolism from infective endocarditis).
Mean age at surgery was 67 years (range 34–92).
The choice of muscles was primarily dictated by the logistics and reproduc-
ibility of sampling, given the variation in level and quantity of discard material
for each amputation, but with a view to including a range of muscle types
(fast, slow, mixed). The original technique of motor point biopsy (for the pero-
neal muscles) as described by Coe¨rs and Woolf (1959) was used as a guide.
For most of the case series, we were able to obtain a complete set of samples
from the four muscles chosen. In total, 72 individual muscles were analyzed
(EDL = 19, S = 18, PB = 18, PL = 17).
Mice and Rats
To allow direct comparison with human NMJs, equivalent muscles were
dissected from both sides of three CD1 littermate mice (adult, 12 weeks
old) and wild-type rats (adult, 16 weeks old). Animals were euthanized with
isoflurane and the muscles dissected out within 30 min post-mortem and fixed
in 4% PFA for 1 hr. All animal experiments were performed under the appro-
priate project and personal licenses granted by the UK Home Office.
Statistical Analysis
All statistical analyses were performed in GraphPad Prism. Individual statisti-
cal tests and significance levels are referred to in the relevant text sections and
corresponding figure legends.
DATA AND SOFTWARE AVAILABILITY
The full raw proteomics data files from this study are freely available for down-
load from: https://datashare.is.ed.ac.uk/handle/10283/2937.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.11.008.
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Figure S1 
 
Figure S1½Comparative anatomy of mouse, rat and human NMJs, Related to 
Figure 1. 
Representative confocal micrographs of NMJs from equivalent muscles in the 3 
different species, arranged from left to right in order of ascending body weight and 
size. There were no discernable differences between mouse and rat NMJs. Scale bar = 
10 µm. 
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Figure S2 
 
 
 
Figure S2½Validation of NMJ-enrichment in human and mouse tissue, Related 
to Figure 4. 
a.  Samples enriched for NMJ content (NMJ) and devoid of NMJ content (muscle) 
were probed to confirm the efficacy of the isolation procedure used (see Methods and 
Figure 4).  Representative LICOR captured images of gels stained for total protein 
load, and membranes probed for a post-synaptic marker (PSD95) and a nuclear 
marker (H2Ax) confirming b. equivalent protein extraction, c. enrichment for post-
synaptic protein and d. de-enrichment for nuclei.  
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Figure S3 
 
 
 
Figure S3½Biolayout expression profile clustering identifies upregulated synaptic 
proteins in NMJ-enriched tissue samples, Related to Figure 4.   
Nodes (spheres) represent individual proteins and edges (lines) reflect the strength of 
correlation (of expression) between proteins.  Node colours represent distinct protein 
clusters based on their expression profile.  The 3D schematic (shown in 4 different 
orientations) displays all proteins from both NMJ-enriched and NMJ-devoid human 
samples; the 5 distinct synaptic protein clusters from the NMJ-enriched samples are 
indicated with arrows. 
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Figure S4 
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Figure S4½Differences in protein composition between human and mouse NMJs, 
Related to Figure 4. 
IPA canonical pathway analysis of proteomics data identified significant alterations in 
the molecular composition of NMJ-enriched samples from humans compared with 
mice.  Several changes in core synaptic pathways such as agrin interactions at the 
NMJ (a), CREB signaling in neurons (b) and axonal guidance signaling (c) were 
identified.  Nodes in red represent proteins more abundant in human samples relative 
to mouse (>20% increased in human); nodes in green represent proteins more 
abundant in mouse samples relative to human (>20% decreased in human); the darker 
the colour of the node, the greater the difference in protein expression.  Grey nodes 
represent proteins that differ by <20% between human and mouse.  Note that each 
pathway includes proteins that are both more and less abundant in human cf. mouse 
samples, indicating that this is not simply an artefact of relative enrichment during 
tissue processing. 
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Table S1 
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Table S1½Baseline morphological data and influence of pre- and post-synaptic 
cells, Related to Figure 1. 
Core variables (1-11) are listed in red, derived variables (12-18) in blue and 
associated nerve and muscle variables (19-21) in green.  The ‘averages’ listed 
(average human NMJ, average mouse NMJ) for each variable represent the mean for 
the complete set of NMJs (2860 human; 960 mouse).  Fold difference (between 
human and mouse NMJ) is the ratio of the larger value relative to the smaller value; 
most NMJ variables (but not all) were larger in mice.  Correlation data is listed as 
coefficient (r, numerical) and significance level (p, asterisk).  [****p< 0.0001, ***p< 
0.001, **p< 0.01, *p< 0.05] 
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Table S2 
 
 
 
Table S2½Patient case series, Related to Figure 2. 
Demographic and clinical details for the complete case series (20 patients).  Age is in 
years.  Abbreviations: m, male; f, female; R, right limb; L, left limb; BKA, below 
knee amputation; AKA, above knee amputation; PVD, peripheral vascular disease; 
DM, diabetes mellitus; n/a, data not available. 
 
 
 
 
 
 
 
Table	S2		Patient	case	series
case	ref age sex side procedure indication DM function
1R 34 m R BKA non	PVD non	DM mobile
1L 34 m L BKA non	PVD non	DM mobile
2 42 f L BKA non	PVD non	DM mobile
3 49 f R BKA non	PVD non	DM mobile
4 49 m R BKA PVD DM mobile
5 50 m R BKA non	PVD non	DM n/a
6 52 f L BKA PVD DM n/a
7 56 f L BKA PVD DM n/a
8 58 m L AKA PVD DM mobile
9 64 m R BKA PVD DM n/a
10 66 m R BKA PVD DM mobile
11 68 m R BKA PVD DM mobile
12 77 m L BKA PVD DM n/a
13 79 m R BKA PVD DM mobile
14 80 m R BKA PVD non	DM n/a
15 80 m R BKA PVD DM mobile
16 84 m L AKA PVD DM mobile
17 85 m R AKA PVD DM n/a
18 89 m L AKA PVD non	DM n/a
19 92 f L BKA PVD non	DM mobile
20 92 m L BKA PVD non	DM n/a
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Table S3 
 
Ingenuity	Canonical	Pathways -log10(p	value) Upregulated	(H	vs	M)	 Downregulated	(H	vs	M)
Oxidative	Phosphorylation 23.90 0/119	(0%) 75/119	(63%)
3-phosphoinositide	Degradation 8.24 4/162	(2%) 64/162	(40%)
D-myo-inositol-5-phosphate	Metabolism 8.18 4/166	(2%) 65/166	(39%)
D-myo-inositol	(1,4,5,6)-tetrakisphosphate	Biosynthesis 7.04 4/147	(3%) 57/147	(39%)
D-myo-inositol	(3,4,5,6)-tetrakisphosphate	Biosynthesis 7.04 4/147	(3%) 57/147	(39%)
tRNA	Charging 6.49 2/82	(2%) 35/82	(43%)
3-phosphoinositide	Biosynthesis 6.24 6/207	(3%) 69/207	(33%)
Glycolysis	I 6.00 0/41	(0%) 22/41	(54%)
Superpathway	of	Inositol	Phosphate	Compounds 5.70 6/253	(2%) 79/253	(31%)
Ethanol	Degradation	II 5.34 1/47	(2%) 24/47	(51%)
Fatty	Acid	β-oxidation	I 5.12 0/45	(0%) 23/45	(51%)
Gluconeogenesis	I 4.93 1/46	(2%) 22/46	(48%)
Glutaryl-CoA	Degradation 4.77 0/26	(0%) 15/26	(58%)
TCA	Cycle	II	(Eukaryotic) 4.69 0/41	(0%) 20/41	(49%)
Oxidative	Ethanol	Degradation	III 4.46 2/33	(6%) 18/33	(55%)
Ethanol	Degradation	IV 4.46 1/36	(3%) 19/36	(53%)
Fatty	Acid	α-oxidation 4.29 1/25	(4%) 15/25	(60%)
Glycogen	Degradation	III 4.15 0/20	(0%) 12/20	(60%)
Tryptophan	Degradation	X	(Mammalian,	via	Tryptamine) 4.04 2/35	(6%) 18/35	(51%)
Glycogen	Degradation	II 3.94 0/18	(0%) 11/18	(61%)
Pyridoxal	5'-phosphate	Salvage	Pathway 3.67 1/75	(1%) 28/75	(37%)
Valine	Degradation	I 3.46 0/35	(0%) 16/35	(46%)
Glutathione	Redox	Reactions	I 3.39 1/29	(3%) 14/29	(48%)
Noradrenaline	and	Adrenaline	Degradation 3.24 1/57	(2%) 23/57	(40%)
D-myo-inositol	(1,4,5)-trisphosphate	Degradation 2.93 0/22	(0%) 11/22	(50%)
Isoleucine	Degradation	I 2.81 0/29	(0%) 13/29	(45%)
Histamine	Degradation 2.70 1/33	(3%) 15/33	(45%)
Putrescine	Degradation	III 2.42 1/35	(3%) 15/35	(43%)
Superoxide	Radicals	Degradation 2.27 0/10	(0%) 6/10	(60%)
Salvage	Pathways	of	Pyrimidine	Ribonucleotides 2.19 1/112	(1%) 33/112	(29%)
Dopamine	Degradation 2.08 1/49	(2%) 18/49	(37%)
Tryptophan	Degradation	III	(Eukaryotic) 2.08 1/49	(2%) 17/49	(35%)
Thioredoxin	Pathway 2.05 1/8	(13%) 5/8	(63%)
Glutathione	Redox	Reactions	II 2.05 1/8	(13%) 5/8	(63%)
Calcium	Transport	I 2.02 0/14	(0%) 8/14	(57%)
Superpathway	of	Geranylgeranyldiphosphate	Biosynthesis	I	(via	Mevalonate)1.97 1/35	(3%) 13/35	(37%)
Ketogenesis 1.88 0/18	(0%) 8/18	(44%)
Ketolysis 1.88 0/18	(0%) 8/18	(44%)
Colanic	Acid	Building	Blocks	Biosynthesis 1.86 1/36	(3%) 15/36	(42%)
Glutathione-mediated	Detoxification 1.84 0/40	(0%) 15/40	(38%)
Pentose	Phosphate	Pathway 1.79 1/22	(5%) 9/22	(41%)
Acetyl-CoA	Biosynthesis	I	(Pyruvate	Dehydrogenase	Complex) 1.78 0/12	(0%) 6/12	(50%)
2-ketoglutarate	Dehydrogenase	Complex 1.77 0/9	(0%) 5/9	(56%)
Branched-chain	α-keto	acid	Dehydrogenase	Complex 1.77 0/9	(0%) 5/9	(56%)
Myo-inositol	Biosynthesis 1.77 0/9	(0%) 5/9	(56%)
Guanosine	Nucleotides	Degradation	III 1.65 0/23	(0%) 10/23	(43%)
Urate	Biosynthesis/Inosine	5'-phosphate	Degradation 1.65 0/23	(0%) 10/23	(43%)
Pyrimidine	Ribonucleotides	Interconversion 1.64 0/54	(0%) 18/54	(33%)
Mevalonate	Pathway	I 1.61 1/27	(4%) 10/27	(37%)
Stearate	Biosynthesis	I	(Animals) 1.56 1/55	(2%) 18/55	(33%)
Pentose	Phosphate	Pathway	(Oxidative	Branch) 1.54 1/10	(10%) 5/10	(50%)
2-oxobutanoate	Degradation	I 1.50 0/17	(0%) 7/17	(41%)
Adenosine	Nucleotides	Degradation	II 1.50 0/28	(0%) 11/28	(39%)
Folate	Transformations	I 1.50 1/28	(4%) 11/28	(39%)
Mitochondrial	L-carnitine	Shuttle	Pathway 1.45 0/21	(0%) 9/21	(43%)
Methionine	Degradation	I	(to	Homocysteine) 1.41 0/25	(0%) 9/25	(36%)
D-myo-inositol	(1,4,5)-Trisphosphate	Biosynthesis 1.39 1/37	(3%) 11/37	(30%)
Phosphatidylglycerol	Biosynthesis	II	(Non-plastidic) 1.39 3/41	(7%) 15/41	(37%)
Purine	Nucleotides	Degradation	II	(Aerobic) 1.39 0/37	(0%) 13/37	(35%)
Superpathway	of	D-myo-inositol	(1,4,5)-trisphosphate	Metabolism1.39 0/33	(0%) 11/33	(33%)
Superpathway	of	Methionine	Degradation 1.38 0/66	(0%) 19/66	(29%)
D-glucuronate	Degradation	I 1.35 1/11	(9%) 5/11	(45%)
Heme	Degradation 1.35 1/11	(9%) 5/11	(45%)
Glucose	and	Glucose-1-phosphate	Degradation 1.33 0/22	(0%) 9/22	(41%)
Pyrimidine	Ribonucleotides	De	Novo	Biosynthesis 1.32 0/67	(0%) 20/67	(30%)
Leucine	Degradation	I 1.31 0/26	(0%) 9/26	(35%)
NADH	Repair 1.30 0/8	(0%) 4/8	(50%)
Glycerol-3-phosphate	Shuttle 1.30 0/8	(0%) 4/8	(50%)
Hypusine	Biosynthesis 1.28 0/5	(0%) 3/5	(60%)
CDP-diacylglycerol	Biosynthesis	I 1.22 3/35	(9%) 13/35	(37%)
Methylglyoxal	Degradation	III 1.22 1/23	(4%) 9/23	(39%)
NAD	Salvage	Pathway	II 1.22 1/35	(3%) 12/35	(34%)
Serotonin	Degradation 1.21 1/91	(1%) 25/91	(27%)
Methylmalonyl	Pathway 1.19 0/12	(0%) 5/12	(42%)
NAD	Phosphorylation	and	Dephosphorylation 1.13 1/20	(5%) 7/20	(35%)
Fatty	Acid	β-oxidation	III	(Unsaturated,	Odd	Number) 1.04 0/6	(0%) 3/6	(50%)
Retinoate	Biosynthesis	I 1.00 1/38	(3%) 11/38	(29%)
Acetate	Conversion	to	Acetyl-CoA 0.96 0/10	(0%) 4/10	(40%)
Pyruvate	Fermentation	to	Lactate 0.96 0/10	(0%) 4/10	(40%)
Tetrahydrofolate	Salvage	from	5,10-methenyltetrahydrofolate 0.96 0/10	(0%) 4/10	(40%)
Trans,	trans-farnesyl	Diphosphate	Biosynthesis 0.96 0/10	(0%) 4/10	(40%)
Acyl-CoA	Hydrolysis 0.94 0/14	(0%) 5/14	(36%)
Aspartate	Degradation	II 0.94 0/14	(0%) 5/14	(36%)
GDP-glucose	Biosynthesis 0.93 0/18	(0%) 7/18	(39%)
Choline	Degradation	I 0.86 0/7	(0%) 3/7	(43%)
GDP-L-fucose	Biosynthesis	I	(from	GDP-D-mannose) 0.86 1/7	(14%) 3/7	(43%)
Proline	Degradation 0.86 0/7	(0%) 3/7	(43%)
Thiosulfate	Disproportionation	III	(Rhodanese) 0.86 0/7	(0%) 3/7	(43%)
Retinol	Biosynthesis 0.86 2/49	(4%) 14/49	(29%)
Chondroitin	Sulfate	Degradation	(Metazoa) 0.85 0/23	(0%) 7/23	(30%)
Heme	Biosynthesis	II 0.85 0/23	(0%) 7/23	(30%)
Sucrose	Degradation	V	(Mammalian) 0.84 0/19	(0%) 6/19	(32%)
Superpathway	of	Serine	and	Glycine	Biosynthesis	I 0.84 0/19	(0%) 6/19	(32%)
Heme	Biosynthesis	from	Uroporphyrinogen-III	I 0.83 0/11	(0%) 4/11	(36%)
Phenylalanine	Degradation	I	(Aerobic) 0.83 0/11	(0%) 4/11	(36%)
Phenylethylamine	Degradation	I 0.83 0/11	(0%) 4/11	(36%)
Rapoport-Luebering	Glycolytic	Shunt 0.83 0/11	(0%) 4/11	(36%)
Prostanoid	Biosynthesis 0.83 1/15	(7%) 4/15	(27%)
Cysteine	Biosynthesis	III	(mammalia) 0.82 0/32	(0%) 9/32	(28%)
Purine	Nucleotides	De	Novo	Biosynthesis	II 0.81 0/41	(0%) 11/41	(27%)
Triacylglycerol	Degradation 0.74 1/56	(2%) 14/56	(25%)
Superpathway	of	Citrulline	Metabolism 0.73 2/38	(5%) 9/38	(24%)
Ascorbate	Recycling	(Cytosolic) 0.73 1/12	(8%) 4/12	(33%)
Biotin-carboxyl	Carrier	Protein	Assembly 0.73 1/12	(8%) 3/12	(25%)
Glycogen	Biosynthesis	II	(from	UDP-D-Glucose) 0.73 0/12	(0%) 4/12	(33%)
N-acetylglucosamine	Degradation	II 0.73 0/12	(0%) 4/12	(33%)
NAD	Biosynthesis	III 0.73 0/12	(0%) 4/12	(33%)
S-methyl-5-thio-α-D-ribose	1-phosphate	Degradation 0.73 0/12	(0%) 4/12	(33%)
Formaldehyde	Oxidation	II	(Glutathione-dependent) 0.72 1/8	(13%) 3/8	(38%)
Geranylgeranyldiphosphate	Biosynthesis 0.72 0/8	(0%) 3/8	(38%)
N-acetylglucosamine	Degradation	I 0.72 0/8	(0%) 3/8	(38%)
Retinoate	Biosynthesis	II 0.72 0/8	(0%) 3/8	(38%)
S-adenosyl-L-methionine	Biosynthesis 0.72 0/8	(0%) 3/8	(38%)
Phospholipases 0.66 0/72	(0%) 17/72	(24%)
Triacylglycerol	Biosynthesis 0.66 1/58	(2%) 16/58	(28%)
Adenine	and	Adenosine	Salvage	III 0.66 0/17	(0%) 5/17	(29%)
Lysine	Degradation	II 0.66 1/17	(6%) 5/17	(29%)
Citrulline	Biosynthesis 0.65 2/26	(8%) 6/26	(23%)
UDP-N-acetyl-D-galactosamine	Biosynthesis	II 0.65 0/26	(0%) 9/26	(35%)
Arginine	Degradation	I	(Arginase	Pathway) 0.63 0/13	(0%) 4/13	(31%)
GDP-mannose	Biosynthesis 0.63 0/13	(0%) 5/13	(38%)
Molybdenum	Cofactor	Biosynthesis 0.63 0/13	(0%) 4/13	(31%)
Pentose	Phosphate	Pathway	(Non-oxidative	Branch) 0.63 0/13	(0%) 4/13	(31%)
Adenine	and	Adenosine	Salvage	I 0.61 0/9	(0%) 3/9	(33%)
Creatine-phosphate	Biosynthesis 0.61 0/9	(0%) 3/9	(33%)
Guanine	and	Guanosine	Salvage	I 0.61 0/9	(0%) 3/9	(33%)
The	Visual	Cycle 0.57 1/32	(3%) 9/32	(28%)
Galactose	Degradation	I	(Leloir	Pathway) 0.55 0/14	(0%) 5/14	(36%)
Proline	Biosynthesis	I 0.55 2/14	(14%) 3/14	(21%)
Serine	Biosynthesis 0.55 0/14	(0%) 4/14	(29%)
Fatty	Acid	Activation 0.52 0/19	(0%) 6/19	(32%)
4-aminobutyrate	Degradation	I 0.52 0/10	(0%) 3/10	(30%)
Thymine	Degradation 0.52 1/10	(10%) 3/10	(30%)
Arginine	Biosynthesis	IV 0.50 1/24	(4%) 6/24	(25%)
γ-linolenate	Biosynthesis	II	(Animals) 0.50 0/24	(0%) 7/24	(29%)
γ-glutamyl	Cycle 0.49 1/29	(3%) 8/29	(28%)
Glycine	Biosynthesis	I 0.48 0/6	(0%) 2/6	(33%)
S-methyl-5'-thioadenosine	Degradation	II 0.48 0/6	(0%) 2/6	(33%)
Purine	Ribonucleosides	Degradation	to	Ribose-1-phosphate 0.47 0/20	(0%) 5/20	(25%)
Glutathione	Biosynthesis 0.44 1/11	(9%) 3/11	(27%)
Uracil	Degradation	II	(Reductive) 0.44 1/11	(9%) 3/11	(27%)
Arginine	Degradation	VI	(Arginase	2	Pathway) 0.43 1/16	(6%) 4/16	(25%)
Citrulline-Nitric	Oxide	Cycle 0.43 1/16	(6%) 4/16	(25%)
Inosine-5'-phosphate	Biosynthesis	II 0.43 0/16	(0%) 4/16	(25%)
Selenocysteine	Biosynthesis	II	(Archaea	and	Eukaryotes) 0.43 0/16	(0%) 4/16	(25%)
D-myo-inositol	(1,3,4)-trisphosphate	Biosynthesis 0.41 0/26	(0%) 6/26	(23%)
Pyrimidine	Deoxyribonucleotides	De	Novo	Biosynthesis	I 0.40 0/41	(0%) 9/41	(22%)
Aspartate	Biosynthesis 0.39 0/7	(0%) 2/7	(29%)
Glutamate	Biosynthesis	II 0.39 1/7	(14%) 2/7	(29%)
Glutamate	Degradation	X 0.39 1/7	(14%) 2/7	(29%)
Glutamine	Biosynthesis	I 0.39 0/7	(0%) 2/7	(29%)
Tyrosine	Biosynthesis	IV 0.39 0/7	(0%) 2/7	(29%)
UDP-D-xylose	and	UDP-D-glucuronate	Biosynthesis 0.39 0/7	(0%) 2/7	(29%)
Glutamate	Degradation	III	(via	4-aminobutyrate) 0.38 0/12	(0%) 3/12	(25%)
CMP-N-acetylneuraminate	Biosynthesis	I	(Eukaryotes) 0.37 0/17	(0%) 4/17	(24%)
UDP-N-acetyl-D-glucosamine	Biosynthesis	II 0.37 0/17	(0%) 4/17	(24%)
Choline	Biosynthesis	III 0.37 0/22	(0%) 5/22	(23%)
Phenylalanine	Degradation	IV	(Mammalian,	via	Side	Chain) 0.37 1/32	(3%) 7/32	(22%)
Superpathway	of	Cholesterol	Biosynthesis 0.36 1/83	(1%) 17/83	(20%)
1D-myo-inositol	Hexakisphosphate	Biosynthesis	II	(Mammalian)0.33 0/28	(0%) 6/28	(21%)
Dermatan	Sulfate	Degradation	(Metazoa) 0.33 0/23	(0%) 5/23	(22%)
Lysine	Degradation	V 0.33 1/23	(4%) 5/23	(22%)
Folate	Polyglutamylation 0.33 0/18	(0%) 4/18	(22%)
Glycerol	Degradation	I 0.32 0/13	(0%) 3/13	(23%)
Glycine	Cleavage	Complex 0.32 0/13	(0%) 3/13	(23%)
L-carnitine	Biosynthesis 0.32 0/13	(0%) 3/13	(23%)
NAD	Salvage	Pathway	III 0.32 0/13	(0%) 3/13	(23%)
Tetrapyrrole	Biosynthesis	II 0.32 0/13	(0%) 3/13	(23%)
Alanine	Biosynthesis	III 0.32 0/3	(0%) 1/3	(33%)
D-mannose	Degradation 0.32 0/3	(0%) 1/3	(33%)
Glutamate	Removal	from	Folates 0.32 0/3	(0%) 1/3	(33%)
Lanosterol	Biosynthesis 0.32 0/3	(0%) 1/3	(33%)
Acetyl-CoA	Biosynthesis	III	(from	Citrate) 0.32 0/8	(0%) 2/8	(25%)
Flavin	Biosynthesis	IV	(Mammalian) 0.32 0/8	(0%) 2/8	(25%)
Methylglyoxal	Degradation	I 0.32 0/8	(0%) 2/8	(25%)
PRPP	Biosynthesis	I 0.32 0/8	(0%) 2/8	(25%)
Xanthine	and	Xanthosine	Salvage 0.32 0/8	(0%) 2/8	(25%)
Proline	Biosynthesis	II	(from	Arginine) 0.29 1/19	(5%) 4/19	(21%)
dTMP	De	Novo	Biosynthesis 0.28 1/14	(7%) 3/14	(21%)
1,25-dihydroxyvitamin	D3	Biosynthesis 0.27 1/9	(11%) 2/9	(22%)
Cardiolipin	Biosynthesis	II 0.27 0/9	(0%) 2/9	(22%)
Epoxysqualene	Biosynthesis 0.27 1/9	(11%) 2/9	(22%)
Glutamate	Degradation	II 0.27 0/9	(0%) 2/9	(22%)
Glycine	Degradation	(Creatine	Biosynthesis) 0.27 0/9	(0%) 2/9	(22%)
L-cysteine	Degradation	III 0.27 0/9	(0%) 2/9	(22%)
Methylglyoxal	Degradation	VI 0.27 0/9	(0%) 2/9	(22%)
Oxidized	GTP	and	dGTP	Detoxification 0.27 0/9	(0%) 2/9	(22%)
Urea	Cycle 0.25 0/20	(0%) 4/20	(20%)
Acyl	Carrier	Protein	Metabolism 0.24 0/4	(0%) 1/4	(25%)
Sulfite	Oxidation	IV 0.24 0/4	(0%) 1/4	(25%)
Trehalose	Degradation	II	(Trehalase) 0.22 0/10	(0%) 3/10	(30%)
β-alanine	Degradation	I 0.22 0/10	(0%) 2/10	(20%)
Adenine	and	Adenosine	Salvage	VI 0.18 0/5	(0%) 1/5	(20%)
Anandamide	Degradation 0.18 0/5	(0%) 1/5	(20%)
Asparagine	Degradation	I 0.18 0/5	(0%) 1/5	(20%)
Glutamine	Degradation	I 0.18 0/5	(0%) 1/5	(20%)
Melatonin	Degradation	III 0.18 0/5	(0%) 1/5	(20%)
Methylthiopropionate	Biosynthesis 0.18 0/5	(0%) 1/5	(20%)
Sorbitol	Degradation	I 0.18 0/5	(0%) 1/5	(20%)
Table	S3		Human	vs	mouse	muscle	metabolic	cascades
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Table S3½Conservation of metabolic cascades between human and mouse muscle 
proteomes, Related to Figure 4.  
Out of the 200 metabolic pathways identified in-silico, only 68 show differential 
proteomic expression between the species (pathways with a –log10(p value) ≥ 1.3).  
66% of the known metabolic cascades are therefore unchanged between human and 
mouse muscle (NMJ-devoid) samples.  Table layout and abbreviations are the same as 
in Figure 4 (panel d).  
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Supplemental Experimental Procedures:  
Tissue harvesting 
Muscle samples were obtained from the amputation specimen in the operating theatre 
immediately after disconnection of the limb.  Tissue was harvested from the proximal 
end of the specimen, close to the line of surgical incision, in areas demonstrating good 
back bleeding and muscle fasciculation, and away from areas of necrosis and 
infection.  Any muscle that appeared obviously devitalized on gross inspection was 
not sampled.  
 
Small blocks of tissue, containing full-length muscle fibres from origin to insertion 
(approx. 2cm in length) were removed from each of the muscles selected and either 
immediately fixed in 4% paraformaldehyde for 1 hour or placed on wet ice 
(depending on the subsequent analyses, see below).  All specimens were then 
transferred from theatre to laboratory for immediate processing. 
 
The major concern relating to the use of tissue harvested from amputation specimens 
is the potential effect of chronic tissue ischaemia and diabetes mellitus (DM).  
Although twelve of the twenty patients had one or other form of diabetes, the 
functional status of all patients (where documented) was commensurate with standing 
and some degree of walking prior to surgery (with one 92-year-old female able to 
walk half a mile; Table S2).   
 
At surgery, the level of amputation is principally determined by the likelihood of 
wound healing; a more distal amputation is the preferred option from a functional 
point of view, but not at the expense of healing.  For the amputation stump to heal 
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fully the local blood supply must be adequate; thus, tissue sampled close to the line of 
incision (level of amputation) should also be of adequate health.  The final decision 
on the level of amputation is determined during the procedure itself, by assessing the 
degree of back bleeding from the stump after disconnection of the limb.  If the tissues 
are clearly devitalized, the amputation is immediately revised to a level at which these 
conditions are satisfied.  These basic principles, along with the frequency with which 
lower limb amputation is performed (over 4,000 per year in England from 2003-2009) 
(Ahmad et al., 2014), provided the rationale for utilizing this method of tissue 
sampling.  In addition, all samples were harvested from muscle that demonstrated 
visible contraction during dissection.  
 
No significant differences were found in mean muscle fibre diameter when comparing 
patients with and without PVD (Figure 1), excluding any significant sarcopenia 
and/or disuse atrophy in the present case series.  Furthermore, no significant 
differences were noted in the majority of the core morphological variables measured, 
when comparing NMJs in patients with or without either PVD (n.s. for 8 of 11 
variables) or diabetes (n.s. for 10 of 11) (Figure 1).  In addition, the general 
appearance of NMJs on visual inspection was remarkably conserved even when 
comparing NMJs at the extremes of the case series (young, non-PVD cf. elderly, 
PVD; Figure 2). 
 
Muscle dissection and NMJ immunohistochemistry 
Following muscle harvest, both human and rodent tissue was processed in an identical 
manner.  Small bundles of 25-30 muscle fibres were teased out from the larger 
blocks/whole muscles, and of a size suitable for whole-mount preparation.  NMJs 
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were then immunolabelled for presynaptic 2H3/SV2 proteins and postsynaptic AChRs 
according to the following protocol (antibodies and concentrations are listed below): 
α-bungarotoxin for 30 minutes; 4% Triton X for 90 minutes; ‘block’ for 30 minutes 
(4% bovine serum albumin and 2% Triton X); primary antibodies (in block) for 3 
nights at 4°C; 4 washes of 1xPBS; secondary antibodies for 1 night at 4°C; 4 washes 
of 1xPBS.  Preparations were then whole-mounted in Mowiol and stored at -20°C 
prior to imaging. 
 
Antibodies 
Primary antibodies: 1:50 mouse anti-2H3 IgG and 1:50 mouse anti-SV2 IgG 
(Developmental Studies Hybridoma Bank).  Secondary antibodies: 1:50 Alexa Fluor 
488 donkey anti-mouse IgG (Thermo Fisher Scientific).  1:500 TRITC α-
bungarotoxin (Biotium). 
 
Confocal imaging and NMJ-morph analysis 
Images were acquired and analyzed using a standardized workflow, ‘NMJ-morph’, as 
previously described (Jones et al., 2016).  Briefly, a Zeiss LSM 710 confocal 
microscope was used to acquire z-stack projections of individual en-face NMJs, 
including a short length of their pre-terminal axon.  Images were then analyzed 
according to the described workflow, which uses ImageJ or Fiji (and freely availably 
plugins) to measure 21 individual pre- and post-synaptic morphological variables.  
Again, based on the NMJ-morph recommendations, 40 NMJs per muscle were 
analyzed to achieve accuracy of reported mean values.  In total, we analyzed 2,860 
individual human NMJs and 960 comparative mouse NMJs. 
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Muscle fibre diameters 
Following confocal microscopy, the teased preparations were re-imaged at x20 
magnification using an Olympus IX71 microscope, Hamamatsu C4742-95 camera 
and Openlab Improvision software.  Measurement of muscle fibre diameter was 
performed manually in ImageJ; again, 40 individual fibres were analyzed per muscle 
(3,820 fibres in total for the complete human/mouse dataset). 
 
dSTORM super-resolution imaging and SNAP25 quantification 
A subset of peroneus longus muscle fibres was selected from three human cases.  For 
comparison, an equivalent set of PL muscle fibres were obtained from three CD1 
mice.  Muscle dissection and immunohistochemistry was performed as described 
above, with the following modifications: after incubation in the primary antibodies 
(rabbit anti-SNAP25 IgG, 1:100; Alomone) for 3 nights at 4°C, tissue samples were 
labeled with Alexa Fluor 647 goat anti-rabbit IgG (1:100; Thermo Fisher Scientific) 
at room temperature for 2 hours.  Specimens were then washed and mounted in 
dSTORM mounting medium (90% glycerol, 1xPBS, 100mM MEA) (Hou et al., 2015).  
Human samples underwent an additional 70-minute treatment with 1mM CuSO4 in 
50mM ammonium acetate buffer, pH5 (Schnell et al., 1999) to remove lipofuscin-
genic autofluorescence after immunolabelling. 
  
Imaging was performed on a customized Nikon Ti Eclipse inverted fluorescent TIRF 
microscope with a 642nm laser.  The lateral stage control was electronic and a piezo 
focuser (P-725, Physik Instrumente, Germany) precisely controlled the axial position.  
30,000-65,000 frames were recorded with a 25ms acquisition time, in a z-step format.  
Z-steps were repeatedly performed at z-intervals of 200nm.  Z-limits were set 
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manually, slightly above and below the plane of interface between nerve terminal and 
motor endplate.  Only switching events in the given focal plane were accepted by a 
thresholding filter as part of the PYME implemented jittered triangulation algorithm 
(Hou et al., 2015).  The same settings were used to capture a 550nm LED illuminated 
widefield stack of TRITC-α-bungarotoxin-labeled AChRs through a Texas Red filter 
set prior to dSTORM imaging.  AChR stacks were used to produce a mean intensity 
projection image to act as a mask. 
 
Quantification of SNAP25 distribution was performed in an identical manner for all 
images, using ImageJ.  The ‘masked’ images (SNAP25/AChR overlays) were used as 
a reference when determining the boundaries of individual boutons/SNAP25 puncta 
on the dSTORM image, from which all measurements were made.  dSTORM images 
of complete NMJs were first cropped to produce a series of images, each centred on 
an individual bouton (human) or section of bouton (mouse).  The cropped dSTORM 
images were then converted into 8 bit grayscale counterparts, from which the mean 
gray value (‘intensity’) could be measured.  These grayscale images were then 
converted into binary counterparts (using default thresholding) for the subsequent 
quantification of puncta.  Binary images produced by default thresholding provided 
accurate representations of the original dSTORM images (i.e. no manual adjustments 
or other thresholding algorithms were required), and this approach was applied 
consistently for all images.  Images were then ‘despeckled’ to sharpen the edges of 
individual puncta, and used to quantify the remaining variables: the average area of 
individual puncta and their density within each bouton, and the total area of all puncta 
relative to that of each bouton.  The derived variable ‘total area of active zones per 
NMJ’ (Figure 3) was calculated by multiplying the latter variable (area of puncta : 
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area of bouton, dSTORM data) by the mean area of synaptic contact for NMJs in 
peroneus longus (baseline morphological data).  Overall, we quantified 50 boutons (n) 
from 10 NMJs, for 3 individual patients/mice (N) – a total of 2,945 (human) and 
10,666 (mice) individual puncta. 
 
Proteomics: tissue sampling 
For proteomic analysis, a further subset of PL muscle fibres was selected from four 
human cases.  An equivalent set of PL muscle fibres was obtained from four CD1 
mice for comparison.  After tissue harvest, muscle dissection was performed on 
unfixed tissue, in a manner otherwise similar to that described above, to obtain small 
bundles of 25-30 muscle fibres.  In order to identify the location of the endplate bands, 
muscle fibres were labelled with α-bungarotoxin for 5 minutes; the NMJ-enriched 
portions of the muscle fibres were then micro-dissected under a Nikon Eclipse 50i 
fluorescence microscope (Figure 4).  NMJ-enriched samples, along with NMJ-devoid 
muscle ‘ends’, were then frozen to -80°C prior to proteomic analysis.  All muscle 
dissection and labelling was performed within 30 minutes post-harvest to limit the 
degree of protein degradation.  
 
Proteomics: protein extraction 
Dissected tissue samples were pooled in M tubes (gentle MACS Miltenyi Biotec).  
Samples were homogenized in label-free extraction buffer [100 mM Tris-HCl (pH7.6) 
4% (w/v) SDS] containing 1% protease cocktail inhibitor (Thermo Fisher, UK) using 
gentle MACS dissociator (Miltenyi Biotec) run on the M tube protein cycle.  Post 
homogenization samples were spun at 300 x g for 2 minutes and left on ice for 20 
minutes.  Homogenates were transferred to Lo-Bind 1.5ml tubes (Sigma Aldrich) and 
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centrifuged at 20,000 x g for 20 minutes at 4°C with the soluble fraction of each 
sample then transferred to new Lo-Bind tubes.  Protein determination using the 
Bicinchoninic acid assay (Pierce, UK) was carried out according to manufacturer’s 
guidelines. 
 
Proteomics: mass spectrometry 
Preparation of samples, quantification and bioinformatics was performed according to 
a standardized protocol (Hughes et al., 2014).  Samples were measured out to achieve 
200ug/ul protein.  DTT was added to give a 10mM final concentration and samples 
were left on a shaker at room temperature for 30 minutes, followed by incubation with 
IAA (50mM final concentration) in the dark for 30 minutes.  2ul DTT (1M) was 
added before samples were frozen.  
 
Hydrophobic and hydrophilic beads (GE HealthCare) were mixed together and 
washed with MQ water.  Beads were transferred to 4 tubes.  Samples were then gently 
added to the beads and mixed/shaken for 2 min.  1% FA was then added to each 
sample (2 min mix), followed by 50% ACN (8 min mix); samples were then 
transferred to a magnetic rack and the supernatant was removed.  Next, 70% EtOH 
was added (1 min mix), followed by removal of the supernatant.  Finally, ACN was 
added (1 min mix) and the supernatant again removed. 
 
Proteins were eluted with 100mM TEAB on a shaker for 10 min.  Trypsin in 1mM 
HCl (1ug/ul) was added to each sample and incubated on a shaker at 30°C for 4-6h.  
A further portion of Trypsin was added and the samples were incubated overnight at 
30°C.  The tryptic peptides were then labelled with 6-plex TMT reagents (Thermo 
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Fisher Scientific) using a protocol supplied by the manufacturer [TMT6plex-Nter126 
& -Lys126 – Human +, TMT6plex-Nter127 & -Lys127 – Human -, TMT6plex-
Nter128 & -Lys128 – Mouse +, TMT6plex-Nter129 & -Lys129 – Mouse -].  The 
labelled peptides were quenched then mixed together.  
 
The mixed sample was fractionated into 22 fractions using High pH reverse phase 
chromatography (Ultimate 3000 from Dionex).  HPLC buffer A was 10mM 
ammonium formate in water (pH=10); HPLC buffer B was 10mM ammonium 
formate in 90% CH3CN (pH=10).  An XBridge peptide BEH column (130Å, 3.5 µm 
2.1 X 150 mm from Waters) was used to separate peptides, with the column 
temperature set to 20°C.  Peptides were eluted from the column using a flow rate of 
200ul/min and a linear gradient of 5% to 60% buffer B in 60min.  40 fractions were 
collected and concatenated into 22 fractions based upon UV signal.  All fractions 
were vacuumed dried and re-suspended in 50 µl 1%FA acid prior to MS analysis. 
 
Fractions were analyzed on a Q-exactive-HF mass spectrometer (Thermo Scientific) 
equipped with Dionex Ultimate 3000 RS and Easyspray column (75 μm x 50 cm, 
PepMap RSLC C18 column, 2 μm, 100 Å).  LC buffer A was 0.1% formic acid in MS 
grade Milli-Q water; LC buffer B was 80% acetonitrile and 0.08% formic acid in MS 
grade Milli-Q water.  The peptides were eluted from the column using a flow rate of 
300nl/min and a linear gradient of 5% to 40% buffer B in 122 min.  The column 
temperature was set to 50°C. 
 
Qexactive HF was performed in data dependent mode: an MS survey scan followed 
by 15 sequential dependent MS2 scans, with the 15 most intense precursor ions 
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selected to be fragmented by Higher Energy Collisional Dissociation (HCD), with the 
isolation window at 0.4 da.  The resolution of the MS1 and MS2 was set at 120,000 
and 60,000 respectively.  The maximum ion injection time for MS1 and MS2 was 
50ms and 200ms respectively. 
 
Proteomics: quantification and bioinformatics analysis 
The raw mass spectrometric data files obtained for each experiment were collated into 
a single quantitated dataset using MaxQuant (Cox and Mann, 2008) and Andromeda 
search engine software (Cox et al., 2011).  Enzyme specificity was set to that of 
trypsin, allowing for cleavage of N-terminal to proline residues and between aspartic 
acid and proline residues.  Other parameters used were: (i) variable modifications, 
deamidation (NQ), oxidation (M), protein N-acetylation, gln ® pyro-glu; (ii) fixed 
modifications, carbamidomethylation (C); (iii) database: uniprot-
reviewed_Mus_A10090_160916 & uniprot-Human-up5640_160516; (iv) Reporter 
ion MS2 – 4 TMT labels: TMT6plex-Nter126 to 129 & TMT6plex-Lys126 to 129; (v) 
MS/MS tolerance: FTMS- 10ppm, ITMS- 0.02 Da; (vi) maximum peptide length, 6; 
(vii) maximum missed cleavages, 2; (viii) maximum of labelled amino acids, 3; and 
(ix) false discovery rate, 1%.  Peptide ratios were calculated using ‘Reporter Intensity’ 
for Mouse +/- samples, Human +/- samples and Human/Mouse +/- samples.  Data 
was normalised using 1/median ratio value for each identified protein group per 
labelled sample.  Proteins were filtered to include candidates identified by >1 peptide 
and demonstrating a >20% change between species.  Filtered data was utilised for all 
bioinformatics statistical analyses including Biolayout Express 3D and Ingenuity 
Pathway Analyses (IPA).  Expression clustering was performed in Biolayout Express 
3D software by applying Markov clustering algorithms to raw proteomic data (MCL 
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2.2).  All graphs were clustered using Pearson correlation r=0.96.  IPA was performed 
as previously described (Wishart et al., 2007) with the interaction data limited as 
follows: direct and indirect interactions; experimentally observed data only; 35 
molecules per network; 10 networks per dataset.  Prediction activation scores (z-
scores) were calculated in IPA.  
 
Proteomics: validation of synaptic enrichment   
Human and mouse pooled samples (10 μg load) were separated by SDS-
polyacrylamide gel electrophoresis on 4–12% precast NuPage Bis-Tris gradient gels 
(Life technologies, UK) and then transferred to PVDF membrane using an iBlot 2 fast 
transfer device (Life Technologies, UK).  The membranes were then blocked using 
Odyssey blocking buffer (Li-cor Biosciences, UK) and incubated with primary 
antibodies according to the manufacturers' instructions.  Secondary antibodies (goat 
anti-rabbit IRDye 680 and donkey anti-mouse IRDye 680, Li-cor Biosciences, UK) 
were added according to the manufacturers' instructions.  Blots were imaged using an 
Odyssey Infrared Imaging System (Li-cor Biosciences, UK).  Scan resolution of the 
instrument ranged from 21 to 339 μm, and blots were imaged at 169 μm.  
Quantification was performed on single channels with the analysis software provided.  
Total protein stained gels were loaded in parallel with those used for membrane 
transfer.  Gels were stained with InstantBlue (Expedeon) to ensure equal sample 
loading and were analysed using the Odyssey Infrared Imaging system as previously 
described (Eaton et al., 2013). 
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